Curis Inc Cash Flow Conversion Efficiency
Curis Inc cash flow conversion efficiency. Based on the latest financial reports, Curis Inc (CRIS) has a cash flow conversion efficiency ratio of -0.708x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.00 Million) by net assets ($12.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Curis Inc (1999–2025)
Cash flow conversion efficiency of Curis Inc from 1999 to 2025. This chart illustrates how Curis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Curis Inc (CRIS) stock price for real-time trading data and today's change.
Curis Inc Cash Flow Conversion Ratio Explained
Curis Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Curis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curis Inc ranked by their cash flow conversion efficiency. Also see Curis Inc (CRIS) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CQS Natural Resources Growth and Income plc
LSE:CYN
|
0.014x |
|
Thai Polycons Public Company Limited
BK:TPOLY
|
0.129x |
|
Newpeak Metals Ltd
AU:NPM
|
-0.132x |
|
Crown Place VCT PLC
LSE:CRWN
|
-0.004x |
|
BioXcel Therapeutics Inc
NASDAQ:BTAI
|
0.053x |
|
Mercia Technologies PLC
LSE:MERC
|
0.032x |
|
Arbuthnot Banking Group Plc
LSE:ARBB
|
0.304x |
|
Accsys Technologies PLC
LSE:AXS
|
0.058x |
Annual Cash Flow Conversion Efficiency for Curis Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Curis Inc from 1999 to 2025. Review how much free cash does Curis Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.46 Million | $-27.20 Million | -4.980x | -175.50% |
| 2024-12-31 | $-6.00 Million | $-39.56 Million | 6.596x | +437.58% |
| 2023-12-31 | $19.67 Million | $-38.43 Million | -1.954x | -67.40% |
| 2022-12-31 | $46.55 Million | $-54.34 Million | -1.167x | -181.44% |
| 2021-12-31 | $90.71 Million | $-37.62 Million | -0.415x | -110.55% |
| 2020-12-31 | $130.67 Million | $-25.74 Million | -0.197x | -125.49% |
| 2019-12-31 | $-33.91 Million | $-26.20 Million | 0.773x | -88.44% |
| 2018-12-31 | $-4.50 Million | $-30.07 Million | 6.687x | +431.80% |
| 2017-12-31 | $23.99 Million | $-48.35 Million | -2.015x | -64.70% |
| 2016-12-31 | $29.27 Million | $-35.81 Million | -1.224x | -164.09% |
| 2015-12-31 | $64.51 Million | $-29.89 Million | -0.463x | +17.92% |
| 2014-12-31 | $29.78 Million | $-16.81 Million | -0.564x | -167.31% |
| 2013-12-31 | $45.17 Million | $-9.54 Million | -0.211x | +52.37% |
| 2012-12-31 | $34.27 Million | $-15.19 Million | -0.443x | -287.44% |
| 2011-12-31 | $39.88 Million | $-4.56 Million | -0.114x | -219.74% |
| 2010-12-31 | $45.52 Million | $-1.63 Million | -0.036x | +84.41% |
| 2009-12-31 | $33.05 Million | $-7.59 Million | -0.230x | +31.30% |
| 2008-12-31 | $37.22 Million | $-12.44 Million | -0.334x | -82.17% |
| 2007-12-31 | $46.84 Million | $-8.59 Million | -0.183x | -10.14% |
| 2006-12-31 | $35.90 Million | $-5.98 Million | -0.167x | +22.23% |
| 2005-12-31 | $38.00 Million | $-8.14 Million | -0.214x | -42.93% |
| 2004-12-31 | $48.91 Million | $-7.33 Million | -0.150x | +40.33% |
| 2003-12-31 | $38.87 Million | $-9.76 Million | -0.251x | +32.68% |
| 2002-12-31 | $18.54 Million | $-6.92 Million | -0.373x | -51.50% |
| 2001-12-31 | $101.02 Million | $-24.88 Million | -0.246x | -76.21% |
| 2000-12-31 | $168.81 Million | $-23.59 Million | -0.140x | +77.84% |
| 1999-12-31 | $23.42 Million | $-14.77 Million | -0.631x | -- |
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. … Read more